search
Back to results

Blood Biomarkers in Suicidal Behaviour (2BSB)

Primary Purpose

Major Depression

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Blood sample for genetic purpose
Sponsored by
University Hospital, Montpellier
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Major Depression focused on measuring Psychiatry, Depressive disorder, Suicidal behavior, Genetics

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

No specific inclusion criteria :

  • 18 to 65 years
  • Subject who signed the informed consent
  • Able to understand the nature, purpose and methodology of the study
  • Able to understand and perform the clinical and neuropsychological evaluations.

Specific inclusion criteria depressed suicide attempters:

  • Subject whose primary psychiatric diagnosis is a major depressive episode according to Diagnostic and Statistical Manual of Mental Disorders -5 (DSM-5) criteria
  • Personal history of suicide attempt

affective controls:

  • Subject whose primary psychiatric diagnosis is a major depressive episode according to DSM-5 criteria
  • No personal history of suicide attempt

healthy controls:

  • No personal history of psychiatric disorders (Axis I ) defined by the Mini International Neuropsychiatric Interview (MINI) according to the DSM-5 criteria
  • No history of suicide attempt

Exclusion criteria

  • Refusal of participation
  • Deprived of liberty Subject (by judicial or administrative decision)
  • Subject protected by law (guardianship)
  • Subject exclusion period in relation to another protocol
  • Subject is not affiliated to a social security scheme, beneficiary or not such a plan
  • Subject for which the maximum annual amount of allowances of € 4,500 has been reached
  • Pregnant women
  • Breastfeeding Women

Sites / Locations

  • University Hospital

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Blood sample for genetic purpose

Arm Description

All the participants performed the same evaluations and blood analysis. The study is composed of 3 groups : depressed patients with an history of suicide attempt depressed patients without any history of suicide attempt healthy controls without any history of psychopathology

Outcomes

Primary Outcome Measures

Evolution of the modification of the expression of Adenosine deaminases acting on RNA (ADARs) and of the editing profile of phospho-diesterase 8A (PDE8A)
Studying ADARs expression and RNA editing of genes associated with SB, including PDE8A and comparison of these results between healthy controls and depressed patients with or without history of SB

Secondary Outcome Measures

Modification of the expression of ADAR1a enzymes
Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Spindle And Kinetochore Associated protein 2 (SKA2)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression of ADAR1b enzymes
Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression of ADAR2 enzymes
Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Spermidine/Spermine N1-Acetyltransferase 1 (SAT1)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Interleukins (ILs)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Chemokines (CXCLs)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Brain derived Neurotrphic factor (BDNF)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Cluster of differentiation 24 (CD24)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Three prime repair exonuclease 1 (TREX1)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Interferon stimulated gene 15 (ISG15)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Tumor necrosis factor alpha (TNF alpha)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Vascular endothelial growth factor (VEGF)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of Hydroxytryptamine receptor 2A (HTR2A)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Modification of the expression and RNA editing of insulin-like growth factor protein 7 (IGFB7)
Comparison between non suicidal and suicidal depressed patients and healthy controls

Full Information

First Posted
July 15, 2016
Last Updated
December 21, 2021
Sponsor
University Hospital, Montpellier
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France, Sys2Diag, Mixt laboratory CNRS/Alcediag, Montpellier
search

1. Study Identification

Unique Protocol Identification Number
NCT02855918
Brief Title
Blood Biomarkers in Suicidal Behaviour
Acronym
2BSB
Official Title
Modification of the Expression of ADARs and PDE8A Editing in Suicidal Behavior
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Completed
Study Start Date
September 23, 2016 (Actual)
Primary Completion Date
June 24, 2020 (Actual)
Study Completion Date
June 24, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France, Sys2Diag, Mixt laboratory CNRS/Alcediag, Montpellier

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Suicidal behavior (SB) is a major public health problem in France, with more than 10,000 suicides and 220,000 suicide attempts per year. According to the commonly accepted model for understanding suicidal behavior, individuals who carry a suicidal act when subjected to stress factors (environmental stress, depression, substance ...) are those which have a specific vulnerability. These vulnerabilities can be considered as clinical parameters (propensity to despair, aggressive and/or impulsive traits), neurobiological parameters (dysfunction of the serotonergic system, ...) and cognitive parameters (taking disadvantageous decision ...). Suicidal vulnerability is partly underpinned by genetic factors. The interest of current researches is to identify biomarkers that will improve the opportunities for early identification of subject with a risk for SB. Numerous scientific studies, including post-mortem studies of the brains of suicide completers, have established a link between dysregulation of the ribonucleic acids editing (RNA) of certain genes, the enzymatic activity of Adenosine deaminases acting on RNA (ADARS) responsible for this edition and suicidal behavior. A prospective study is needed to quantify and qualify in the blood of depressed patients (with or without a history of suicide) and healthy controls, the editing changes and the expression and alteration of the activity of ADARS.
Detailed Description
Over two years, 600 participants will be recruited: 225 subjects with current major depressive episode and an history of suicide attempt (depressed suicide attempters) 225 subjects with current major depressive episode but with no personal history of suicide attempt (affective controls) 150 subjects with no history of psychopathology whole life (healthy controls) Each patient will attend a total of 3visits during a follow-up period of 6 months +/- 15 days (inclusion, visit at 3 and 6 months).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depression
Keywords
Psychiatry, Depressive disorder, Suicidal behavior, Genetics

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
600 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Blood sample for genetic purpose
Arm Type
Other
Arm Description
All the participants performed the same evaluations and blood analysis. The study is composed of 3 groups : depressed patients with an history of suicide attempt depressed patients without any history of suicide attempt healthy controls without any history of psychopathology
Intervention Type
Other
Intervention Name(s)
Blood sample for genetic purpose
Intervention Description
All the participants will performed the same evaluations and blood analysis : A clinical assessment by psychiatrist Self report questionnaires for the assessment of a potential mood disorder and history of SB, moral/physical pain, personality traits… A neuropsychological assessment for the evaluations of cognitive performances A routine blood sampling to the realization of a standard blood test A specific blood sampling (PAXgene® tubes) to extract total RNA of blood cells and measure the expression of ADARS RNA and editing of the PDE8A transcript.
Primary Outcome Measure Information:
Title
Evolution of the modification of the expression of Adenosine deaminases acting on RNA (ADARs) and of the editing profile of phospho-diesterase 8A (PDE8A)
Description
Studying ADARs expression and RNA editing of genes associated with SB, including PDE8A and comparison of these results between healthy controls and depressed patients with or without history of SB
Time Frame
At the inclusion visit, 3 months and 6 months after the inclusion
Secondary Outcome Measure Information:
Title
Modification of the expression of ADAR1a enzymes
Description
Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls
Time Frame
At the inclusion visit, 3 months and 6 months after the inclusion
Title
Modification of the expression and RNA editing of Spindle And Kinetochore Associated protein 2 (SKA2)
Description
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time Frame
At the inclusion visit, 3 months and 6 months after the inclusion
Title
Modification of the expression of ADAR1b enzymes
Description
Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls
Time Frame
At the inclusion visit, 3 months and 6 months after the inclusion
Title
Modification of the expression of ADAR2 enzymes
Description
Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls
Time Frame
At the inclusion visit, 3 months and 6 months after the inclusion
Title
Modification of the expression and RNA editing of Spermidine/Spermine N1-Acetyltransferase 1 (SAT1)
Description
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time Frame
At the inclusion visit, 3 months and 6 months after the inclusion
Title
Modification of the expression and RNA editing of Interleukins (ILs)
Description
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time Frame
At the inclusion visit, 3 months and 6 months after the inclusion
Title
Modification of the expression and RNA editing of Chemokines (CXCLs)
Description
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time Frame
At the inclusion visit, 3 months and 6 months after the inclusion
Title
Modification of the expression and RNA editing of Brain derived Neurotrphic factor (BDNF)
Description
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time Frame
At the inclusion visit, 3 months and 6 months after the inclusion
Title
Modification of the expression and RNA editing of Cluster of differentiation 24 (CD24)
Description
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time Frame
At the inclusion visit, 3 months and 6 months after the inclusion
Title
Modification of the expression and RNA editing of Three prime repair exonuclease 1 (TREX1)
Description
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time Frame
At the inclusion visit, 3 months and 6 months after the inclusion
Title
Modification of the expression and RNA editing of Interferon stimulated gene 15 (ISG15)
Description
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time Frame
At the inclusion visit, 3 months and 6 months after the inclusion
Title
Modification of the expression and RNA editing of Tumor necrosis factor alpha (TNF alpha)
Description
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time Frame
At the inclusion visit, 3 months and 6 months after the inclusion
Title
Modification of the expression and RNA editing of Vascular endothelial growth factor (VEGF)
Description
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time Frame
At the inclusion visit, 3 months and 6 months after the inclusion
Title
Modification of the expression and RNA editing of Hydroxytryptamine receptor 2A (HTR2A)
Description
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time Frame
At the inclusion visit, 3 months and 6 months after the inclusion
Title
Modification of the expression and RNA editing of insulin-like growth factor protein 7 (IGFB7)
Description
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time Frame
At the inclusion visit, 3 months and 6 months after the inclusion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
No specific inclusion criteria : 18 to 65 years Subject who signed the informed consent Able to understand the nature, purpose and methodology of the study Able to understand and perform the clinical and neuropsychological evaluations. Specific inclusion criteria depressed suicide attempters: Subject whose primary psychiatric diagnosis is a major depressive episode according to Diagnostic and Statistical Manual of Mental Disorders -5 (DSM-5) criteria Personal history of suicide attempt affective controls: Subject whose primary psychiatric diagnosis is a major depressive episode according to DSM-5 criteria No personal history of suicide attempt healthy controls: No personal history of psychiatric disorders (Axis I ) defined by the Mini International Neuropsychiatric Interview (MINI) according to the DSM-5 criteria No history of suicide attempt Exclusion criteria Refusal of participation Deprived of liberty Subject (by judicial or administrative decision) Subject protected by law (guardianship) Subject exclusion period in relation to another protocol Subject is not affiliated to a social security scheme, beneficiary or not such a plan Subject for which the maximum annual amount of allowances of € 4,500 has been reached Pregnant women Breastfeeding Women
Facility Information:
Facility Name
University Hospital
City
Montpêllier
ZIP/Postal Code
34295
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Blood Biomarkers in Suicidal Behaviour

We'll reach out to this number within 24 hrs